H J Adam

Summary

Affiliation: University of Manitoba
Country: Canada

Publications

  1. ncbi Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study
    Heather J Adam
    Department of Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
    Diagn Microbiol Infect Dis 69:307-13. 2011
  2. ncbi Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination
    H J Adam
    Department of Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Vaccine 28:4073-8. 2010
  3. ncbi In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates
    Heather J Adam
    Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 53:4915-20. 2009
  4. ncbi Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 56:769-72. 2005
  5. ncbi Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates
    Heather J Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 58:202-4. 2006
  6. ncbi Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006
    Heather J Adam
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 730 William Ave, Winnipeg, Manitoba R3E0W3, Canada
    Int J Antimicrob Agents 34:82-5. 2009
  7. ncbi Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005
    Heather J Adam
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 51:198-207. 2007
  8. ncbi Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 0W3
    Int J Antimicrob Agents 28:266-9. 2006
  9. ncbi Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005
    Kimberly A Nichol
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 52:1190-4. 2008
  10. ncbi Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study
    Kimberly A Nichol
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
    Diagn Microbiol Infect Dis 69:320-5. 2011

Detail Information

Publications12

  1. ncbi Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study
    Heather J Adam
    Department of Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
    Diagn Microbiol Infect Dis 69:307-13. 2011
    ..9%]). The most active agents against Gram-negative bacilli were carbapenems (e.g., meropenem and ertapenem) and piperacillin-tazobactam, while for Gram-positive cocci, they were vancomycin, linezolid, and daptomycin...
  2. ncbi Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination
    H J Adam
    Department of Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Vaccine 28:4073-8. 2010
    ..influenzae infection now commonly presents as sepsis due to non-typeable H. influenzae in older individuals. However, strain replacement of Hib with serotype f and non-typeable strains in children under 5 years was documented...
  3. ncbi In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates
    Heather J Adam
    Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 53:4915-20. 2009
    ..015 to > or = 512; Klebsiella pneumoniae, 2/< or = 0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to > or = 512; Pseudomonas aeruginosa, 32/< or = 0.015 to > or = 512; Acinetobacter baumannii, 1/0.12 to 16)...
  4. ncbi Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 56:769-72. 2005
    ....
  5. ncbi Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates
    Heather J Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 58:202-4. 2006
    ....
  6. ncbi Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006
    Heather J Adam
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 730 William Ave, Winnipeg, Manitoba R3E0W3, Canada
    Int J Antimicrob Agents 34:82-5. 2009
    ..Ciprofloxacin usage appears to be the biggest driver of resistance; however, total fluoroquinolone usage is also important...
  7. ncbi Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005
    Heather J Adam
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 51:198-207. 2007
    ..Continued surveillance and molecular analysis of fluoroquinolone-resistant S. pneumoniae in Canada are essential for appropriate empirical treatment of infections and early detection of novel resistance mechanisms...
  8. ncbi Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 0W3
    Int J Antimicrob Agents 28:266-9. 2006
    ..Additionally, we propose that the use of a second fluoroquinolone marker, such as ciprofloxacin, offers the best prediction for detecting an isolate possessing a first-step parC mutation...
  9. ncbi Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005
    Kimberly A Nichol
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 52:1190-4. 2008
    ..Increased genetic homogeneity among the isolates from 2003 to 2005 (cluster analysis; P < 0.001) appeared to be due to expansion of existing clonal groups and to introduction of new PFGE types...
  10. ncbi Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study
    Kimberly A Nichol
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
    Diagn Microbiol Infect Dis 69:320-5. 2011
    ..No MRSA resistance occurred with linezolid, daptomycin, or tigecycline. In conclusion, CA-MRSA genotypes represented 25.2% of all MRSA and continue to increase in prevalence in Canadian hospitals...
  11. ncbi In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study
    James A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
    Diagn Microbiol Infect Dis 69:342-7. 2011
    ..Based on their robust in vitro activities, dalbavancin and telavancin have the potential to treat Gram-positive infections caused by methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae...
  12. ncbi Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2228-30. 2006
    ..Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC...